Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall
{"title":"CYP2C19表型间戊脒耐受性和疗效的评估。","authors":"Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall","doi":"10.2217/pgs-2023-0093","DOIUrl":null,"url":null,"abstract":"<p><p>Intravenous pentamidine is used for prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by <i>CYP2C19</i>, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as <i>P. jirovecii</i> pneumonia prophylaxis. The primary objective was the association between <i>CYP2C19</i> phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and <i>P. jirovecii</i> pneumonia infection rates were low.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"821-830"},"PeriodicalIF":1.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of pentamidine tolerability and efficacy between <i>CYP2C19</i> phenotypes.\",\"authors\":\"Alexis Koon, Jiaxian He, Jai Patel, Allison Morse, Victoria Boseman, Alicia Hamilton, Thomas Knight, Nilay Shah, Brittany Ragon, Aleksander Chojecki, Jing Ai, Nury Steuerwald, Jonathan Gerber, Edward Copelan, Michael Grunwald, Justin Arnall\",\"doi\":\"10.2217/pgs-2023-0093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Intravenous pentamidine is used for prophylaxis against <i>Pneumocystis jirovecii</i> pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by <i>CYP2C19</i>, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as <i>P. jirovecii</i> pneumonia prophylaxis. The primary objective was the association between <i>CYP2C19</i> phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and <i>P. jirovecii</i> pneumonia infection rates were low.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":\" \",\"pages\":\"821-830\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0093\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes.
Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia prophylaxis. The primary objective was the association between CYP2C19 phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (N = 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (p = 0.18) or discontinuation due to side effects (p = 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475). Drug discontinuation rates and P. jirovecii pneumonia infection rates were low.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
